ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Stocks in this Quantisnow insightHealth Care
Historical context for PRQR
Across the 17 sessions after earlier PRQR headlines, the stock closed higher 10 times and lower 7 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PRQR | SPY |
|---|---|---|---|
| Sep 2, 2026 | ProQR to Participate in Upcoming Investor Conferences in September 2026 | +1.4% | +0.4% |
| Aug 20, 2026 | BofA Securities initiated coverage on ProQR Therapeutics with a new price target | +2.3% | -0.8% |
| Aug 13, 2026 | ProQR Announces Second Quarter 2026 Operating and Financial Results | -0.5% | +0.7% |
| Jun 25, 2026 | ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placementand 1 other headline that session | -13.5% | +0.1% |
| May 12, 2026 | ProQR Announces First Quarter 2026 Operating and Financial Results | -0.6% | -0.2% |
| May 11, 2026 | ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform | +1.9% | +0.2% |
Quantisnow market dataNASDAQ
PRQR
ProQR Therapeutics N.V.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for PRQR
Full PRQR profile on Quantisnow Follow PRQR and get a push notification the moment its next story breaks.